Reuters logo
BRIEF-Ionis Pharmaceuticals reports phase 1/2 clinical study results with AKCEA-ANGPTL3-L
May 25, 2017 / 11:39 AM / 7 months ago

BRIEF-Ionis Pharmaceuticals reports phase 1/2 clinical study results with AKCEA-ANGPTL3-L

May 25 (Reuters) - Ionis Pharmaceuticals Inc

* Reports phase 1/2 clinical study results with AKCEA-ANGPTL3-L

* Says AKCEA-ANGPTL3-L was well tolerated with no serious adverse events Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below